Loading
A phase 2/3 trial of PRL3-ZUMAB in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, now recruiting.
Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients is a phase 2/3 interventional study registered as NCT07290088 by Intra-IMMUSG Pte Ltd, with 52 participants planned, started 2023-01-09 and due to reach its primary completion in 2026-12. Interventions recorded: PRL3-ZUMAB.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Intra-IMMUSG, PTP4A3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Intra-IMMUSG, PTP4A3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/